Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 5309 | 29.18 |
09:34 ET | 822 | 29.365 |
09:36 ET | 5037 | 29.22 |
09:38 ET | 600 | 29.52 |
09:39 ET | 100 | 29.53 |
09:41 ET | 300 | 29.355 |
09:43 ET | 300 | 29.365 |
09:45 ET | 700 | 29.5059 |
09:48 ET | 4211 | 29.27 |
09:50 ET | 400 | 29.3 |
09:52 ET | 2700 | 29.38 |
09:54 ET | 500 | 29.36 |
09:56 ET | 14479 | 29.485 |
09:57 ET | 300 | 29.485 |
09:59 ET | 4400 | 29.54 |
10:01 ET | 2097 | 29.5 |
10:03 ET | 1909 | 29.515 |
10:06 ET | 2156 | 29.49 |
10:08 ET | 500 | 29.42 |
10:10 ET | 3217 | 29.46 |
10:12 ET | 8837 | 29.49 |
10:14 ET | 8342 | 29.535 |
10:15 ET | 500 | 29.495 |
10:17 ET | 11777 | 29.475 |
10:19 ET | 713 | 29.46 |
10:21 ET | 5725 | 29.31 |
10:24 ET | 5568 | 29.26 |
10:26 ET | 1360 | 29.245 |
10:28 ET | 1700 | 29.42 |
10:30 ET | 2910 | 29.3 |
10:32 ET | 3474 | 29.25 |
10:33 ET | 3344 | 29.32 |
10:35 ET | 11476 | 29.26 |
10:37 ET | 4459 | 29.33 |
10:39 ET | 4050 | 29.36 |
10:42 ET | 16518 | 29.365 |
10:44 ET | 600 | 29.37 |
10:46 ET | 3250 | 29.51 |
10:48 ET | 3600 | 29.3 |
10:50 ET | 6305 | 29.28 |
10:51 ET | 2000 | 29.335 |
10:53 ET | 814 | 29.34 |
10:55 ET | 800 | 29.35 |
10:57 ET | 3770 | 29.25 |
11:00 ET | 300 | 29.24 |
11:02 ET | 600 | 29.265 |
11:04 ET | 100 | 29.3 |
11:06 ET | 500 | 29.3 |
11:08 ET | 6412 | 29.34 |
11:09 ET | 800 | 29.31 |
11:11 ET | 300 | 29.35 |
11:13 ET | 3406 | 29.2 |
11:15 ET | 500 | 29.16 |
11:18 ET | 300 | 29.13 |
11:20 ET | 8425 | 29.22 |
11:22 ET | 700 | 29.23 |
11:24 ET | 200 | 29.28 |
11:26 ET | 900 | 29.24 |
11:27 ET | 400 | 29.29 |
11:29 ET | 1034 | 29.28 |
11:31 ET | 300 | 29.26 |
11:33 ET | 888 | 29.305 |
11:36 ET | 200 | 29.3 |
11:38 ET | 5141 | 29.38 |
11:40 ET | 500 | 29.39 |
11:42 ET | 200 | 29.455 |
11:44 ET | 500 | 29.5 |
11:45 ET | 3504 | 29.39 |
11:47 ET | 200 | 29.37 |
11:49 ET | 760 | 29.42 |
11:51 ET | 1093 | 29.39 |
11:54 ET | 500 | 29.42 |
11:56 ET | 4506 | 29.48 |
11:58 ET | 7543 | 29.44 |
12:00 ET | 5455 | 29.4 |
12:02 ET | 500 | 29.48 |
12:03 ET | 1976 | 29.5 |
12:05 ET | 500 | 29.51 |
12:07 ET | 17483 | 29.395 |
12:09 ET | 500 | 29.45 |
12:12 ET | 3395 | 29.34 |
12:14 ET | 3770 | 29.4 |
12:16 ET | 1427 | 29.41 |
12:18 ET | 12002 | 29.45 |
12:20 ET | 10054 | 29.43 |
12:21 ET | 850 | 29.44 |
12:23 ET | 1000 | 29.525 |
12:25 ET | 1000 | 29.525 |
12:27 ET | 1700 | 29.515 |
12:30 ET | 1900 | 29.56 |
12:32 ET | 2342 | 29.465 |
12:34 ET | 813 | 29.5 |
12:36 ET | 400 | 29.5 |
12:38 ET | 1100 | 29.44 |
12:39 ET | 203 | 29.45 |
12:41 ET | 200 | 29.47 |
12:43 ET | 700 | 29.44 |
12:45 ET | 400 | 29.41 |
12:48 ET | 1200 | 29.44 |
12:50 ET | 1423 | 29.475 |
12:52 ET | 1312 | 29.45 |
12:54 ET | 400 | 29.47 |
12:56 ET | 400 | 29.5 |
12:57 ET | 200 | 29.485 |
12:59 ET | 300 | 29.49 |
01:01 ET | 800 | 29.51 |
01:03 ET | 3437 | 29.63 |
01:06 ET | 1500 | 29.62 |
01:08 ET | 957 | 29.645 |
01:10 ET | 2136 | 29.64 |
01:12 ET | 720 | 29.65 |
01:14 ET | 2056 | 29.625 |
01:15 ET | 3995 | 29.62 |
01:17 ET | 500 | 29.68 |
01:19 ET | 500 | 29.76 |
01:21 ET | 3718 | 29.87 |
01:24 ET | 1099 | 29.84 |
01:26 ET | 700 | 29.92 |
01:28 ET | 1845 | 29.968 |
01:30 ET | 3978 | 29.92 |
01:32 ET | 200 | 29.965 |
01:33 ET | 873 | 29.9377 |
01:35 ET | 400 | 29.98 |
01:37 ET | 1514 | 29.94 |
01:39 ET | 2219 | 29.978 |
01:42 ET | 1005 | 29.9553 |
01:44 ET | 7069 | 29.98 |
01:46 ET | 4879 | 30 |
01:48 ET | 8614 | 29.98 |
01:50 ET | 1150 | 29.98 |
01:51 ET | 1280 | 29.96 |
01:53 ET | 2353 | 29.93 |
01:55 ET | 440 | 29.93 |
01:57 ET | 1800 | 29.96 |
02:00 ET | 300 | 29.97 |
02:02 ET | 2524 | 29.885 |
02:04 ET | 1400 | 29.93 |
02:06 ET | 200 | 29.91 |
02:08 ET | 2673 | 29.96 |
02:09 ET | 700 | 29.98 |
02:11 ET | 5072 | 29.98 |
02:13 ET | 3805 | 29.97 |
02:15 ET | 1246 | 29.965 |
02:18 ET | 700 | 29.93 |
02:20 ET | 500 | 29.95 |
02:22 ET | 700 | 29.95 |
02:24 ET | 700 | 29.955 |
02:26 ET | 1877 | 29.92 |
02:27 ET | 1161 | 29.85 |
02:29 ET | 200 | 29.8625 |
02:31 ET | 400 | 29.84 |
02:33 ET | 600 | 29.875 |
02:36 ET | 2324 | 29.91 |
02:38 ET | 1976 | 29.88 |
02:40 ET | 1300 | 29.905 |
02:42 ET | 700 | 29.915 |
02:44 ET | 5571 | 29.91 |
02:45 ET | 6189 | 29.94 |
02:47 ET | 1467 | 29.98 |
02:49 ET | 4311 | 30.025 |
02:51 ET | 3340 | 30.01 |
02:54 ET | 300 | 30.01 |
02:56 ET | 1800 | 30.11 |
02:58 ET | 1100 | 30.15 |
03:00 ET | 3456 | 30.01 |
03:02 ET | 1509 | 29.95 |
03:03 ET | 1100 | 29.975 |
03:05 ET | 2983 | 29.9 |
03:07 ET | 13002 | 29.91 |
03:09 ET | 2138 | 29.9 |
03:12 ET | 3250 | 29.9 |
03:14 ET | 1652 | 29.9 |
03:16 ET | 850 | 29.9 |
03:18 ET | 900 | 29.895 |
03:20 ET | 2533 | 29.8 |
03:21 ET | 1161 | 29.825 |
03:23 ET | 2724 | 29.8842 |
03:25 ET | 600 | 29.84 |
03:27 ET | 200 | 29.87 |
03:30 ET | 1868 | 29.85 |
03:32 ET | 800 | 29.87 |
03:34 ET | 2223 | 29.85 |
03:36 ET | 6140 | 29.89 |
03:38 ET | 4123 | 29.87 |
03:39 ET | 2735 | 29.82 |
03:41 ET | 3554 | 29.79 |
03:43 ET | 3877 | 29.785 |
03:45 ET | 1423 | 29.8 |
03:48 ET | 4810 | 29.67 |
03:50 ET | 3952 | 29.78 |
03:52 ET | 8294 | 29.75 |
03:54 ET | 5924 | 29.79 |
03:56 ET | 9634 | 29.78 |
03:57 ET | 17784 | 29.75 |
03:59 ET | 196792 | 29.67 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 4.3B | -15.5x | --- |
Crinetics Pharmaceuticals Inc | 4.3B | -14.3x | --- |
Avidity Biosciences Inc | 4.9B | -14.1x | --- |
BridgeBio Pharma Inc | 4.9B | -9.9x | --- |
Biohaven Ltd | 3.6B | -4.2x | --- |
Madrigal Pharmaceuticals Inc | 5.3B | -9.5x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.92 |
Book Value | $4.24 |
P/E Ratio | -15.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.